{"id":4147,"date":"2017-12-25T12:17:25","date_gmt":"2017-12-25T11:17:25","guid":{"rendered":"http:\/\/wordpress.p545550.webspaceconfig.de\/uncategorized\/pitch-day-im-izb\/"},"modified":"2020-07-14T12:14:04","modified_gmt":"2020-07-14T10:14:04","slug":"pitch-day-at-the-izb","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/pitch-day-at-the-izb\/","title":{"rendered":"Pitch Day at the IZB"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

Pitch Day at the IZB
\n<\/span><\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]December 2017[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”4143″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 IZB[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Dr. Timothy Luker, Senior Director Emerging Technology & Innovation, Business Development, Eli Lilly, Dr. David Moller, Vice President, Emerging Technology & Innovation, Business Development, Eli Lilly, Dr. Peter Hanns Zobel, CEO, IZB, Dr. Karin Kleinhans, Partner bei LSP \/ Partner at LSP, \u00adDr. Stephen Curtis, Senior Director Emerging Technology & Innovation, Business Development, Eli Lilly, Dr. Marianne Mertens, Investment Manager, High-Tech Gr\u00fcnderfonds, Dr. Georg Ried, Gesch\u00e4ftsf\u00fchrer \/ Managing Director, Bayern Kapital (v.l.n.r.).
\nEbenfalls teilgenommen (nicht im Bild) \/ also participated (not pictured): Prof. Dr. Patrick Baeuerle, Gesch\u00e4ftsf\u00fchrer \/ Managing Director, MPM Capital[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text]At the request of Eli Lilly, the IZB organized a second pitchday this year. The goal was to network more closely with the local venture capital scene, and to get to know new Martinsried Campus projects. On November 9, 2017, seven representatives of pharmaceutical and venture capital firms met at the Faculty Club G2B to present the interesting projects of the IZB start-ups and early stage projects.
\n\u201cWe were impressed by the Martinsried Campus and the interesting start-ups at the IZB. The relatively unique combination of the high-quality incubator facilities, experienced leadership at the IZB, and productive relationships with innovators and venture capitalists make this a very attractive place for Eli Lilly. Many of the projects, especially in the early-stage area, fit well with the strategy of Eli Lilly. We will continue to keep a close eye on the location and certainly participate in such events again,\u201d said Dr. Tim Luker, Senior Director of Emerging Technology & Innovation, Global Corporate Development, who was accompanied by Dr. David Moller, Vice President, and Dr. Stephen Curtis, Senior Director at Eli Lilly.
\n\u201cThe following companies presented their projects: Manfred Gr\u00f6ppel, Managing Director of Immunic AG; Dr. Michael Thormann, Managing Director of Origenis GmbH; Claus Schalper, Managing Director of XL-Protein, Nadja Fenn, workgroup Prof. Karl-Peter Hopfner, Gene Center at the Ludwig Maximilian University Munich (LMU), and the team of Moritz V\u00f6lker-Albert and Prof. Axel Imhof from the Biomedical Center of the LMU. The last thing that V\u00f6lker-Albert said was: \u201cNow I have successfully completed the first pitchday of my life!\u201c
\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n